Literature DB >> 26524196

Nanotechnology Approaches for the Delivery of Exogenous siRNA for HIV Therapy.

Simeon K Adesina1, Emmanuel O Akala1.   

Abstract

RNA interference (RNAi) is triggered by oligonucleotides that are about 21-23 nucleotides long and are capable of inducing the destruction of complementary mRNA. The RNAi technique has been successfully utilized to target HIV replication; however, the main limitation to the successful utilization of this technique in vivo is the inability of naked siRNA to cross the cell membrane by diffusion due to its strong anionic charge and large molecular weight. This review describes current nonviral nanotechnological approaches to deliver anti-HIV siRNAs for the treatment of HIV infection.

Entities:  

Keywords:  RNA interference (RNAi); dendrimers; liposomes; polymeric nanoparticles; small interfering RNA

Mesh:

Substances:

Year:  2015        PMID: 26524196      PMCID: PMC5586487          DOI: 10.1021/acs.molpharmaceut.5b00335

Source DB:  PubMed          Journal:  Mol Pharm        ISSN: 1543-8384            Impact factor:   4.939


  99 in total

Review 1.  Biocompatible quantum dots for biological applications.

Authors:  Sandra J Rosenthal; Jerry C Chang; Oleg Kovtun; James R McBride; Ian D Tomlinson
Journal:  Chem Biol       Date:  2011-01-28

Review 2.  Delivery of siRNA therapeutics: barriers and carriers.

Authors:  Jie Wang; Ze Lu; M Guillaume Wientjes; Jessie L-S Au
Journal:  AAPS J       Date:  2010-06-11       Impact factor: 4.009

3.  Systemic administration of combinatorial dsiRNAs via nanoparticles efficiently suppresses HIV-1 infection in humanized mice.

Authors:  Jiehua Zhou; C Preston Neff; Xiaoxuan Liu; Jane Zhang; Haitang Li; David D Smith; Piotr Swiderski; Tawfik Aboellail; Yuanyu Huang; Quan Du; Zicai Liang; Ling Peng; Ramesh Akkina; John J Rossi
Journal:  Mol Ther       Date:  2011-09-27       Impact factor: 11.454

Review 4.  Cell-type-specific aptamer and aptamer-small interfering RNA conjugates for targeted human immunodeficiency virus type 1 therapy.

Authors:  Jiehua Zhou; John Rossi
Journal:  J Investig Med       Date:  2014-10       Impact factor: 2.895

5.  Preparation and characterization of nanoparticles containing an atypical antipsychotic agent.

Authors:  Sanjay Singh; Madaswamy S Muthu
Journal:  Nanomedicine (Lond)       Date:  2007-04       Impact factor: 5.307

6.  T cell-specific siRNA delivery suppresses HIV-1 infection in humanized mice.

Authors:  Priti Kumar; Hong-Seok Ban; Sang-Soo Kim; Haoquan Wu; Todd Pearson; Dale L Greiner; Amale Laouar; Jiahong Yao; Viraga Haridas; Katsuyoshi Habiro; Yong-Guang Yang; Ji-Hoon Jeong; Kuen-Yong Lee; Yong-Hee Kim; Sung Wan Kim; Matthias Peipp; Georg H Fey; N Manjunath; Leonard D Shultz; Sang-Kyung Lee; Premlata Shankar
Journal:  Cell       Date:  2008-08-07       Impact factor: 41.582

7.  Formation and degradation of poly(D,L-lactide) nanoparticles and their potential application as controllable releasing devices.

Authors:  Yue Zhao; Jie Fu; Dennis K P Ng; Chi Wu
Journal:  Macromol Biosci       Date:  2004-09-16       Impact factor: 4.979

8.  Novel dual inhibitory function aptamer-siRNA delivery system for HIV-1 therapy.

Authors:  Jiehua Zhou; Haitang Li; Shirley Li; John Zaia; John J Rossi
Journal:  Mol Ther       Date:  2008-05-06       Impact factor: 11.454

9.  Carbon Nanotubes: Solution for the Therapeutic Delivery of siRNA?

Authors:  D Lynn Kirkpatrick; Michelle Weiss; Anton Naumov; Geoffrey Bartholomeusz; R Bruce Weisman; Olga Gliko
Journal:  Materials (Basel)       Date:  2012-02-13       Impact factor: 3.623

Review 10.  Recent developments in nanoparticle-based siRNA delivery for cancer therapy.

Authors:  Jong-Min Lee; Tae-Jong Yoon; Young-Seok Cho
Journal:  Biomed Res Int       Date:  2013-06-17       Impact factor: 3.411

View more
  15 in total

1.  Non-covalent Encapsulation of siRNA with Cell-Penetrating Peptides.

Authors:  Martina Tuttolomondo; Henrik J Ditzel
Journal:  Methods Mol Biol       Date:  2021

Review 2.  The role of nanotechnology in the treatment of viral infections.

Authors:  Lavanya Singh; Hendrik G Kruger; Glenn E M Maguire; Thavendran Govender; Raveen Parboosing
Journal:  Ther Adv Infect Dis       Date:  2017-07-05

Review 3.  Nanotechnology approaches to eradicating HIV reservoirs.

Authors:  Shijie Cao; Kim A Woodrow
Journal:  Eur J Pharm Biopharm       Date:  2018-06-04       Impact factor: 5.571

Review 4.  Cellular Delivery of RNA Nanoparticles.

Authors:  Lorena Parlea; Anu Puri; Wojciech Kasprzak; Eckart Bindewald; Paul Zakrevsky; Emily Satterwhite; Kenya Joseph; Kirill A Afonin; Bruce A Shapiro
Journal:  ACS Comb Sci       Date:  2016-08-26       Impact factor: 3.784

Review 5.  The therapeutic landscape of HIV-1 via genome editing.

Authors:  Alexander Kwarteng; Samuel Terkper Ahuno; Godwin Kwakye-Nuako
Journal:  AIDS Res Ther       Date:  2017-07-14       Impact factor: 2.250

6.  Studies on polyethylene glycol-monoclonal antibody conjugates for fabrication of nanoparticles for biomedical applications.

Authors:  Funmilola Fisusi; Nailah Brandy; Jingbo Wu; Emmanuel O Akala
Journal:  J Nanosci Nanomed       Date:  2020-02-03

Review 7.  Recent advances in materials science: a reinforced approach toward challenges against COVID-19.

Authors:  Abhinav Saxena; Deepak Khare; Swati Agrawal; Angaraj Singh; Ashutosh Kumar Dubey
Journal:  Emergent Mater       Date:  2021-02-22

Review 8.  Recent applications and strategies in nanotechnology for lung diseases.

Authors:  Wenhao Zhong; Xinyu Zhang; Yunxin Zeng; Dongjun Lin; Jun Wu
Journal:  Nano Res       Date:  2021-01-08       Impact factor: 8.897

Review 9.  Recent advances in siRNA delivery mediated by lipid-based nanoparticles.

Authors:  Sei Yonezawa; Hiroyuki Koide; Tomohiro Asai
Journal:  Adv Drug Deliv Rev       Date:  2020-08-06       Impact factor: 15.470

10.  CD4+ T Cell-Mimicking Nanoparticles Broadly Neutralize HIV-1 and Suppress Viral Replication through Autophagy.

Authors:  Gang Zhang; Grant R Campbell; Qiangzhe Zhang; Erin Maule; Jonathan Hanna; Weiwei Gao; Liangfang Zhang; Stephen A Spector
Journal:  mBio       Date:  2020-09-15       Impact factor: 7.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.